CCM
NKTR icon

Coldstream Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Coldstream Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-944
Closed -$9.95K – 856
2023
Q1 		$9.95K Sell
944
-20
-2% -$605 ﹤0.01% 831
2022
Q4 		$32.7K Buy
+964
New +$46.7K ﹤0.01% 805
2018
Q4 		– Sell
-453
Closed -$414K – 366
2018
Q3 		$414K Sell
453
-2
-0.4% -$1.71K 0.04% 226
2018
Q2 		$333K Sell
455
-20
-4% -$23.1K 0.03% 240
2018
Q1 		$757K Buy
475
+15
+3% +$19.3K 0.08% 149
2017
Q4 		$412K Buy
+460
New +$272K 0.04% 208

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Coldstream Capital Management's NKTR Position: Q2 2023 in Review

Coldstream Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 944 shares — an estimated $9.95K sold.

Coldstream Capital Management first reported a position in NKTR in Q4 2017 and held it in 6 quarters. The position peaked at $757K in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Coldstream Capital Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Coldstream Capital Management sold 944 Nektar Therapeutics shares in Q2 2023, an estimated $9.95K.
  • Coldstream Capital Management first reported a position in Nektar Therapeutics in Q4 2017 and held it in 6 quarters.
  • Coldstream Capital Management's Nektar Therapeutics position peaked at $757K in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Coldstream Capital Management's 13F filing for Q2 2023, filed 3 Aug 2023.